Movement

fitness_center Exercise & Movement

What exercise studies show, why responses vary, and how to discuss an individual movement plan.

event Editorial update September 2026
Explanation
Important medical disclaimer

This is a patient-written educational guide, not individualized medical advice. Use it to prepare for appointments and ask better questions, but make decisions about exercise, cardiac screening, pacing, and recovery decisions with qualified clinicians who know your case. If you are unwell or unsure how this applies to you, seek medical advice.

Why Exercise Is Complicated

Movement can help some people maintain or improve function, but the right amount depends on your health. Research supports tailored activity, with limits to what small studies can tell us about long-term benefit and safety. Selected mitochondrial myopathy studies support potential training benefits. Small heterogeneous cohorts and limited controlled follow-up require individual prescription and caution in extrapolation. 1234

Mitochondria need these proteins to make energy efficiently. If protein production is disrupted, cells may struggle to meet their energy needs. The effect is not identical in every tissue. Impaired mitochondrial translation can compromise respiratory-chain function and oxidative phosphorylation. Biochemical expression varies with tissue, heteroplasmy and other factors. 567

Muscles may have difficulty meeting increased energy needs during activity. Fatigue, pain and breathlessness deserve attention, but they are not all caused by lactic acidosis. Impaired oxidative capacity can limit exercise tolerance. Symptoms are multifactorial; exertional lactate changes do not establish lactic acidosis or explain every symptom. 12348

Individual limits
Plan around your symptoms and abilities
Gradual changes
Agree how to start and adjust activity
Heart health
Discuss assessment with your team

What Exercise Studies Show

Small supervised studies have found improvements in exercise capacity or muscle measures. Benefits are not guaranteed, and research has not established one programme for everyone. Training trials report potential improvements in capacity and muscle function, with low certainty about optimal prescription and long-term outcomes. 123

Training adaptations

Training can increase the muscle’s capacity to use energy. These changes have been measured in some studies, but they do not mean the DNA change has been cured. Training adaptations can include increased oxidative capacity and mitochondrial enzyme measures; this is not genetic correction. 123

Potential functional benefits

Some participants improve strength or stamina. Whether this makes everyday life easier differs between people and studies. Strength, endurance and patient-reported outcomes vary between interventions and populations; clinically meaningful functional benefit is not established universally. 123

Addressing deconditioning

Long periods of inactivity may add to weakness. If movement is difficult, ask about small adaptations or support rather than assuming you should push harder. Deconditioning can contribute to functional limitation. Rehabilitation should match baseline capacity and comorbidities. 24

What training cannot promise

Do not judge success by a promised change in mutation percentage. Exercise studies do not establish a reliable way to lower your overall mutation load. Training is not a validated heteroplasmy-reduction treatment; measured tissue changes cannot be assumed to represent whole-body genetic benefit. 123910

The Risks of Overexertion

Exercise needs to fit your heart, muscle, neurological and general health. High demands may be unsuitable for some people, even if others tolerate them. Risk assessment should address cardiopulmonary, myopathic, neurological and metabolic limitations rather than impose a universal threshold. 24

warning Metabolic crisis

Stop and get help for severe or unusual symptoms. Chest pain, fainting, severe breathing difficulty or new neurological symptoms need emergency assessment. Severe cardiorespiratory symptoms, syncope or acute neurological change during activity require urgent assessment. 2411

dangerous Rhabdomyolysis

Severe unexpected muscle pain, weakness or dark urine can signal muscle breakdown, called rhabdomyolysis. Seek urgent medical care rather than waiting for normal recovery. Rhabdomyolysis can present with marked myalgia, weakness or myoglobinuria and requires urgent assessment; symptoms cannot be safely attributed to routine post-exercise soreness. 12

cardiology Cardiac concerns

The heart muscle or its electrical system can be affected. A person may need checks even before symptoms become obvious. Cardiomyopathy and conduction or rhythm abnormalities can occur in mitochondrial disease; symptoms may not reflect the full degree of involvement. 4

Planning Activity With Your Team

Build your activity plan with your clinical team or a professional familiar with mitochondrial disease. Use an individual exercise prescription informed by phenotype, function and comorbidity. 24

1

Discuss heart health

Discuss heart assessment before increasing activity. Your team decides which tests are needed using your symptoms, diagnosis and previous results. Pre-exercise cardiac assessment and surveillance should reflect genotype, symptoms, baseline findings and planned activity. 24

2

Start low, go slow

Begin with an amount you can manage and adjust it gradually with your team. Look at how you feel during activity and afterwards; there is no universal safe heart rate or recovery deadline. Individualise intensity, duration and progression, using symptoms and recovery alongside clinical assessment; fixed heart-rate or 48-hour cut-offs are not validated for all patients. 24

3

Discuss endurance and strength activities

Your plan may include gentle aerobic activity and some strength work. The balance depends on your function and goals. Aerobic and resistance components may be considered; evidence is strongest in small selected myopathy cohorts and prescription remains individualised. 1234

4

Agree the support you need

A physiotherapist or exercise professional can help adapt movement to your symptoms, balance and medical needs. Relevant rehabilitation professionals can tailor modality, progression and monitoring to neuromuscular and cardiopulmonary status. 24

5

Allow for illness, heat and recovery

Pause and ask for advice when you are unwell or cannot eat and drink normally. Follow your personal illness plan before returning to exercise. Intercurrent illness, reduced intake or metabolic instability may require modification or temporary cessation of training and clinical reassessment. 2411

6

Agree when to pause or seek help

Stop if you develop unusual pain, dizziness, palpitations or breathlessness. Seek urgent help for severe symptoms; do not continue just to complete a planned session. New exertional symptoms warrant stopping and assessment; severity and persistence determine urgency, with emergency evaluation for red flags. 2411

Movement Options to Discuss

These are options to discuss, not a programme to follow as written. Choose activities that fit your ability, access and care plan. Illustrative modalities require individual adaptation; they are not a validated standard protocol. 24

Walking

Walking or a supported indoor route may be an option. Agree distance, breaks and any mobility support with your team. Walking can be adapted for baseline endurance, balance, orthotic or mobility-aid requirements. 24

Swimming / water exercise

Water activity may be an option after assessment. Discuss safe supervision, especially if you have seizures, weakness or balance problems. Aquatic activity requires assessment of neurological, cardiopulmonary and supervision needs. 24

Stationary cycling

A stationary bike may make it easier to adjust effort. Your team can help choose the position, resistance and session length. Cycle ergometry allows adjustable workload; positioning and duration should match function and clinical status. 24

Yoga & stretching

Gentle stretching or seated movement may be easier on some days. Ask for adaptations if balance, pain or weakness limits movement. Flexibility and seated activities can be adapted to mobility, pain and balance limitations. 24

Light resistance training

If strength work is appropriate, ask a therapist to choose movements, resistance and rest periods that fit you. Individualise resistance exercises, load, repetitions and recovery to myopathic and functional status. 24

Activities needing individual review

Ask for an individual review before strenuous sport, heavy lifting, long events or activity in extreme temperatures. Do not copy a demanding online programme. High-demand, prolonged or thermally stressful activity requires individual assessment; general-population programmes should not be extrapolated without adaptation. 24

Recovery & Monitoring

check_circle Signs of a good session
  • Activity stayed within the limits you agreed. Activity remained within the individual prescription. 24
  • No new or concerning pain developed. No new concerning pain or muscle symptoms. 24
  • Recovery followed your usual pattern. Recovery was consistent with the individual baseline. 24
  • You could manage your usual essential activities afterwards. No significant compromise of subsequent essential function. 24
warning Red flags - stop and seek help
  • Dark or tea-coloured urine Dark urine or possible myoglobinuria 12
  • Severe or worsening muscle pain Marked or progressive myalgia 12
  • Chest pain, fainting or severe breathlessness Chest pain, syncope or severe dyspnoea 411
  • Recovery much worse than usual: contact your team Unusually prolonged recovery: reassess the programme 24
  • Confusion or persistent vomiting after activity Encephalopathy or persistent post-exertional vomiting 411

Track your exercise

A short activity and symptom log can help describe patterns at appointments. Record what you did and how you felt later, using paper or an app you already find useful. A short activity and symptom log can help describe patterns at appointments. Record what you did and how you felt later, using paper or an app you already find useful.

emergency

When to seek urgent medical care

Severe or new symptoms need prompt medical assessment. Use your personal emergency plan and share your diagnosis with the treating team. New neurological symptoms or severe systemic illness require prompt assessment and the individual emergency plan. 411

warning Seek urgent medical care now if:
  • New weakness, speech or vision changes, confusion, a severe new headache or a new seizure. Acute focal deficits, visual disturbance, encephalopathy, severe new headache or new seizures. 411
  • Persistent vomiting, inability to keep food or fluids down, or rapid deterioration. Persistent emesis, inability to maintain intake or rapid clinical deterioration. 4
  • Chest pain, fainting or severe breathing difficulty. Chest pain, syncope or severe dyspnoea. 411
  • Severe abdominal pain or swelling with repeated vomiting. Severe abdominal pain or distension with recurrent emesis. 41113
  • Severe unexpected muscle pain or weakness, especially with dark urine. Marked unexpected myalgia or weakness, particularly with possible myoglobinuria. 12

Bring your personalised emergency letter, medicine and allergy list, and specialist contacts. Clinicians need to consider mitochondrial and other possible causes. Provide the individual emergency plan, medication reconciliation, allergies and specialist contacts; maintain a broad differential diagnosis. 4

description Open Emergency Letter clinical_notes Questions for your doctor

References

13 sources

Sources for the information on this page.

  1. Jeppesen TD, Schwartz M, Olsen DB, Wibrand F, Krag T, Dunø M, Hauerslev S, Vissing J. (2006). Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain : a journal of neurology. Research articleDOI↑ Back to text
  2. Wan Q, Ding Y, Liu W, Yang K. (2026). Effects of exercise training on skeletal muscle function in patients with mitochondrial myopathy: a systematic review. Frontiers in sports and active living. Systematic reviewDOIFull text↑ Back to text
  3. Horne JT, Allen NE, Paul SS, Walker J, Sue C. (2026). MITO-VATION: Feasibility of a technology-supported structured home exercise program in Mitochondrial Disease. PLOS digital health. Research articleDOIFull text↑ Back to text
  4. Sue CM, Balasubramaniam S, Bratkovic D, Bonifant C, Christodoulou J, Coman D, Crawley K, Edema-Hildebrand F, Ellaway C, Ghaoui R, Kava M, Kearns LS, Lee J, Liang C, Mackey DA, Murray S, Needham M, Rius R, Russell J, Smith NJC, Thyagarajan D, Wools C. (2022). Patient care standards for primary mitochondrial disease in Australia: an Australian adaptation of the Mitochondrial Medicine Society recommendations. Internal medicine journal. Clinical guidanceDOIFull text↑ Back to text
  5. Goto Y, Nonaka I, Horai S. (1990). A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. Research articleDOI↑ Back to text
  6. El-Hattab AW, Adesina AM, Jones J, Scaglia F. (2015). MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Molecular genetics and metabolism. ReviewDOI↑ Back to text
  7. Suzuki T, Suzuki T, Wada T, Saigo K, Watanabe K. (2002). Taurine as a constituent of mitochondrial tRNAs: new insights into the functions of taurine and human mitochondrial diseases. The EMBO journal. Research articleDOIFull text↑ Back to text
  8. Klein IL, Verhaak CM, Smeitink JAM, de Laat P, Janssen MCH, Custers JAE. (2022). Identifying trajectories of fatigue in patients with primary mitochondrial disease due to the m.3243A > G variant. Journal of inherited metabolic disease. Research articleDOIFull text↑ Back to text
  9. Pickett SJ, Grady JP, Ng YS, Gorman GS, Schaefer AM, Wilson IJ, Cordell HJ, Turnbull DM, Taylor RW, McFarland R. (2018). Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors. Annals of clinical and translational neurology. Research articleDOIFull text↑ Back to text
  10. Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, Feeney CL, Bright AA, Schaefer AM, Gorman GS, McNally RJ, Taylor RW, Turnbull DM, McFarland R. (2018). mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. EMBO molecular medicine. Research articleDOIFull text↑ Back to text
  11. Mancuso M, Bellusci M, Carelli V, de Coo I, Diodato D, Distelmaier F, Hikmat O, Hirano M, Horvath R, Karaa A, Klopstock T, Koenig MK, Kornblum C, La Morgia C, Lopriore P, Martikainen MH, McFarland R, Musumeci O, Pitceathly RDS, Primiano G, Rahman S, Scaglia F, Schaefer A, Schiff M, Semmler L, Lamperti C, Servidei S. (2026). Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements. European journal of neurology. Clinical guidanceDOIFull text↑ Back to text
  12. Centers for Disease Control and Prevention / NIOSH (accessed 2026). Signs and Symptoms of Rhabdomyolysis . Official guidance↑ Back to text
  13. de Laat P, Zweers HE, Knuijt S, Smeitink JA, Wanten GJ, Janssen MC. (2015). Dysphagia, malnutrition and gastrointestinal problems in patients with mitochondrial disease caused by the m3243A>G mutation. The Netherlands journal of medicine. Research article↑ Back to text

Browse the research library for papers grouped by topic.

Keep exploring

Related pages

Related pages you may find interesting.

arrow_forwardDaily Lifearrow_forwardNutrition & Dietarrow_forwardSelf Care
chatGive feedback
favorite Support